Silexion Therapeutics Corp 8-K

What Happened

• Silexion Therapeutics Corp. (SLXN) filed a Form 8-K on May 13, 2026 (Item 7.01) to disclose that it has initiated Good Manufacturing Practice (GMP) clinical supply manufacturing for its drug candidate SIL204 with a leading global contract development and manufacturing organization (CDMO). The company furnished a press release titled “Silexion Therapeutics Announces Initiation of GMP Clinical Supply Manufacturing of SIL204 with Leading Global CDMO” as Exhibit 99.1 to the filing.

Key Details

• Filing date: May 13, 2026 (Form 8-K, Item 7.01 — Regulation FD Disclosure).
• Program: SIL204 — initiation of GMP clinical supply manufacturing.
• Partner: described as a “leading global CDMO” in the press release; no specific CDMO name disclosed in the 8-K.
• Press release furnished as Exhibit 99.1 (also noted in Item 9.01).

Why It Matters

• Initiating GMP clinical supply manufacturing is a concrete, non‑speculative development in the SIL204 program and is a necessary step to produce drug material for clinical studies. For investors, this indicates Silexion is advancing from preclinical/early development toward supplying material needed for human trials, reducing a manufacturing-related milestone risk. The filing itself is a Regulation FD disclosure and provides the company’s public notice of this operational progress.